논문KCI 등재
Genetic insights into sarcomatoid hepatocellular carcinoma: Critical role of ARID2 in pathogenesis and immune feature: Editorial on “Integrated molecular characterization of sarcomatoid hepatocellular carcinoma”
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
참고문헌 (22)
관련 논문AI추천
Correspondence to editorial on “Integrated molecular characterization of sarcomatoid hepatocellular carcinoma”Rong-Qi Sun, Shao-Lai Zhou대한간학회 · Clinical and Molecular Hepatology2025 · 제31권 제2호Integrated molecular characterization of sarcomatoid hepatocellular carcinomaBo Wang, Cheng-Li Song, Jia Fan, Jian Zhou, Jing-Yue Pan, Long Chen, Ning Li, Rong-Qi Sun, Shao-Lai Zhou, Si-Yuan Pan, Ye Xu, Yu-Hang Ye, Zheng-Jun Zhou, Zhi-Qiang Hu대한간학회 · Clinical and Molecular Hepatology2025 · 제31권 제2호Personalized approaches to the treatment of hepatocellular carcinoma using immune checkpoint inhibitors: Editorial on “Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial”Naoshi Nishida대한간학회 · Clinical and Molecular Hepatology2025 · 제31권 제1호Correspondence to editorial on “Molecular classifica tion of hepatocellular carcinoma based on zoned met abolic feature and oncogenic signaling pathway”Masatoshi Kudo, Naoshi Nishida, Tomoko Aoki대한간학회 · Clinical and Molecular Hepatology2026 · 제32권 제1호Correspondence to editorial 2 on “Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: insights from the IMbrave150 trial”Ahmed O. Kaseb, Ji Hoon Kim, Ju-Seog Lee, Sung Hwan Lee, Sunyoung S. Lee, Sun Young Yim대한간학회 · Clinical and Molecular Hepatology2025 · 제31권 제1호Correspondence to editorial 1 on “Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: insights from the IMbrave150 Trial”Ahmed O. Kaseb, Ji Hoon Kim, Ju-Seog Lee, Sung Hwan Lee, Sunyoung S. Lee, Sun Young Yim대한간학회 · Clinical and Molecular Hepatology2025 · 제31권 제1호
이 간행물의 다른 논문 (84건)
Epidemiology of metabolic dysfunction-associated steatotic liver diseaseLinda Henry, Markos Kalligeros, Zobair M. Younossipp. 32-50Role of noninvasive tests in the prognostication of metabolic dysfunction-associated steatotic liver diseaseJimmy Che-To Lai, Sherlot Juan Song, Terry Cheuk-Fung Yip, Vincent Wai-Sun Wong, Grace Lai-Hung Wong, Yichong Jiang, Yue Wangpp. 51-75Precision medicine and nucleotide-based therapeutics to treat steatotic liver diseaseAndrea Caddeo, Stefano Romeopp. 76-93Microbiome-centered therapies for the management of metabolic dysfunction-associated steatotic liver diseaseJasmohan S. Bajaj, Jeremy Burton, Antonio Gil-Gómez, Huma Saeed, Juan Pablo Arab, Luis Antonio Díaz, Manuel Romero-Gomez, Marco Arrese, Mohammad Qasim Khanpp. 94-111Alcohol-associated liver disease: Natural history, management and novel targeted therapiesHugo López-Pelayo, Edilmar Alvarado-Tapias, Ana Clemente-Sánchez, Ramón Bataller, Jordi Gratacós-Ginès, Elisa Posepp. 112-133